Enliven has cash runway into late 2026
Enliven Therapeutics has enough cash on hand to fund operations into late 2026 and through multiple milestones for two of its drug candidate.
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
Edgewise Therapeutics Inc., a Boulder-based muscle disease biopharmaceutical company, increased its research and development spending…
-
Enliven Therapeutics finished the third quarter with $292 million in cash, which, the company said,…
-
Medical-device firm Boulder iQ has nearly doubled its Boulder footprint with the purchase of a…
-
Biodesix Inc. (Nasdaq: BDSX), a life-sciences company that specializes in developing tools to detect lung…
